Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Opposes DXA Reimbursement Cuts

Kelly Tyrrell  |  October 31, 2016

The Centers for Medicare and Medicaid Services (CMS) plans to significantly reduce reimbursement for dual-energy X-ray absorptiometry (DXA),—used to measure bone density, diagnose osteoporosis and help prevent fractures—performed as a hospital outpatient service in the 2017 Hospital Outpatient Prospective Payment System (HOPPS). If finalized, by 2023 it will cut payment for the DXA testing by 37%.

Where the ACR Stands & Why
The reduction follows a 75% decline in reimbursement for DXA performed in physicians’ offices since 2006. The ACR has worked with a coalition of state rheumatology societies, professional organizations and advocacy groups to author a letter to the CMS expressing opposition to these new cuts. The letter’s long list of authors includes the Black Women’s Health Imperative, the Philadelphia Rheumatism Society and the United States Bone and Joint Imperative.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although randomized controlled trials have not shown that DXA testing prevents fractures, indirect and observational evidence shows that it “saves lives and money,” says ACR member and incoming chair of the Government Affairs Committee, Angus Worthing, MD, FACP, FACR.1

For example, between 2009 and 2014, when office-based reimbursement was sharply declining, 2.3 million fewer DXA tests were performed.2 Between 2008 and 2015, Dr. Worthing says, osteoporosis diagnoses dropped by 17%, with a concomitant increase in surprise hip fractures (no prior osteoporosis diagnosis) of 14%.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“An elderly woman who goes to the hospital for a bone density test now faces the risk that the hospital may not offer it,” Dr. Worthing says. “It appears that lower reimbursement in a fee-for-service system correlates with less utilization.”

Consequences of the Cuts
Medicare’s reimbursement cuts for office-based DXA testing were projected to save $2.8 billion over five years.3 However, recent estimates show that these cuts led to more than 5,000 deaths and an additional $1 billion in Medicare hip fracture-related expenditures between 2009 and 2014.2

“One-quarter of [elderly] people die within the first year of a hip fracture,” says Dr. Worthing. “And Medicare ends up spending a lot of money on these patients because they are often hospitalized and may require an operation.”

A 2007 study in the Journal of Bone and Mineral Research found that osteoporosis leads to 2 million fractures in the U.S. each year, a number expected to hit 3 million by 2025, at a cost of $34 billion annually.4

“There is cause for concern regarding whether and how Medicare beneficiaries will maintain access to a proven and noninvasive preventive service from their providers if the proposed [HOPPS] cuts are implemented,” the coalition letter says.

Page: 1 2 | Single Page
Share: 

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:bipartisan bill H.R.2461dual-energy x-ray absorptiometryDXAreimbursement cuts

Related Articles

    Payments Cut to the Bone

    February 1, 2007

    CMS reduces reimbursement for DXA and vertebral fracture assessment

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Reading Rheum

    May 1, 2009

    Handpicked Reviews of Contemporary Literature

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences